Date: 2011-04-04
Type of information: Licensing agreement
Compound: homologous recombination technology
Company: Cellectis (France) undisclosed drug company
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: Cellectis has signed a license agreement with an undisclosed pharmaceutical company covering certain uses of its homologous recombination technology patents and patent applications, in the oncology therapeutic field.
Financial terms: The agreement has triggered an immediate payment of €3M ($4.2M) to Cellectis.
Latest news:
